Our findings argue for the therapeutic potential of approaches focused on maximizing the impact on CD4+ Th-ctx activity through manipulation of the Blimp-1/Bcl6 axis in tumor-reactive CD4+ T cells. This evidence concerns the gene PRDM1 and neoplasm.